nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—HBA1—Effects of Nitric Oxide—MB—muscle cancer	0.127	0.722	CbGpPWpGaD
Mefloquine—ABCB1—Dactinomycin—muscle cancer	0.0648	0.236	CbGbCtD
Mefloquine—HBA1—hindlimb—muscle cancer	0.0416	0.144	CbGeAlD
Mefloquine—ABCB1—Vincristine—muscle cancer	0.0399	0.145	CbGbCtD
Mefloquine—HBA2—hindlimb—muscle cancer	0.0382	0.132	CbGeAlD
Mefloquine—ABCB1—Etoposide—muscle cancer	0.0366	0.133	CbGbCtD
Mefloquine—HBA1—appendage—muscle cancer	0.0357	0.123	CbGeAlD
Mefloquine—HBA2—appendage—muscle cancer	0.0328	0.113	CbGeAlD
Mefloquine—ABCB1—Doxorubicin—muscle cancer	0.025	0.0908	CbGbCtD
Mefloquine—ABCB1—Methotrexate—muscle cancer	0.0242	0.088	CbGbCtD
Mefloquine—CYP3A4—Vincristine—muscle cancer	0.0239	0.0871	CbGbCtD
Mefloquine—CYP2D6—Doxorubicin—muscle cancer	0.0235	0.0856	CbGbCtD
Mefloquine—CYP3A4—Etoposide—muscle cancer	0.0219	0.0798	CbGbCtD
Mefloquine—BCHE—diaphragm—muscle cancer	0.0204	0.0705	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—muscle cancer	0.015	0.0544	CbGbCtD
Mefloquine—HBA2—embryo—muscle cancer	0.0109	0.0376	CbGeAlD
Mefloquine—HBA1—renal system—muscle cancer	0.00898	0.031	CbGeAlD
Mefloquine—HBA2—smooth muscle tissue—muscle cancer	0.00856	0.0295	CbGeAlD
Mefloquine—HBA2—renal system—muscle cancer	0.00824	0.0284	CbGeAlD
Mefloquine—HBA1—bone marrow—muscle cancer	0.00679	0.0234	CbGeAlD
Mefloquine—HBA2—bone marrow—muscle cancer	0.00623	0.0215	CbGeAlD
Mefloquine—HBA1—head—muscle cancer	0.00601	0.0207	CbGeAlD
Mefloquine—HBA1—testis—muscle cancer	0.0058	0.02	CbGeAlD
Mefloquine—HBA2—head—muscle cancer	0.00552	0.019	CbGeAlD
Mefloquine—HBA2—testis—muscle cancer	0.00533	0.0184	CbGeAlD
Mefloquine—ADORA1—renal system—muscle cancer	0.0037	0.0128	CbGeAlD
Mefloquine—ADORA1—cardiac atrium—muscle cancer	0.00332	0.0114	CbGeAlD
Mefloquine—ADORA1—tendon—muscle cancer	0.00289	0.00998	CbGeAlD
Mefloquine—ACHE—tendon—muscle cancer	0.00287	0.00992	CbGeAlD
Mefloquine—ADORA2A—head—muscle cancer	0.00287	0.0099	CbGeAlD
Mefloquine—ADORA2A—testis—muscle cancer	0.00277	0.00957	CbGeAlD
Mefloquine—ADORA1—vagina—muscle cancer	0.00268	0.00926	CbGeAlD
Mefloquine—ADORA1—head—muscle cancer	0.00248	0.00855	CbGeAlD
Mefloquine—ADORA1—testis—muscle cancer	0.00239	0.00826	CbGeAlD
Mefloquine—ACHE—testis—muscle cancer	0.00238	0.00821	CbGeAlD
Mefloquine—HBA1—Selenium Micronutrient Network—PTGS2—muscle cancer	0.00236	0.0134	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIDINS220—muscle cancer	0.00208	0.0118	CbGpPWpGaD
Mefloquine—ACHE—Melatonin metabolism and effects—FOXO1—muscle cancer	0.00199	0.0113	CbGpPWpGaD
Mefloquine—CYP19A1—FSH signaling pathway—FOXO1—muscle cancer	0.00194	0.011	CbGpPWpGaD
Mefloquine—BCHE—smooth muscle tissue—muscle cancer	0.00188	0.00649	CbGeAlD
Mefloquine—HBA1—Folate Metabolism—TP53—muscle cancer	0.00177	0.01	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—FH—muscle cancer	0.00174	0.00986	CbGpPWpGaD
Mefloquine—CYP19A1—head—muscle cancer	0.00168	0.0058	CbGeAlD
Mefloquine—CYP19A1—testis—muscle cancer	0.00162	0.0056	CbGeAlD
Mefloquine—BCHE—cardiac atrium—muscle cancer	0.00162	0.00559	CbGeAlD
Mefloquine—ADORA2A—Signaling by NGF—KIDINS220—muscle cancer	0.0016	0.00908	CbGpPWpGaD
Mefloquine—BCHE—bone marrow—muscle cancer	0.00137	0.00472	CbGeAlD
Mefloquine—ADORA2A—GPCRs, Other—CNR1—muscle cancer	0.00133	0.00754	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—FH—muscle cancer	0.00131	0.00747	CbGpPWpGaD
Mefloquine—BCHE—vagina—muscle cancer	0.00131	0.00452	CbGeAlD
Mefloquine—CYP3A4—renal system—muscle cancer	0.00122	0.0042	CbGeAlD
Mefloquine—BCHE—head—muscle cancer	0.00121	0.00418	CbGeAlD
Mefloquine—CYP2D6—renal system—muscle cancer	0.0012	0.00414	CbGeAlD
Mefloquine—BCHE—testis—muscle cancer	0.00117	0.00404	CbGeAlD
Mefloquine—ABCB1—embryo—muscle cancer	0.00114	0.00393	CbGeAlD
Mefloquine—ACHE—Metabolism of proteins—TIMM10—muscle cancer	0.00105	0.00596	CbGpPWpGaD
Mefloquine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	0.001	0.00568	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—MED12—muscle cancer	0.00098	0.00557	CbGpPWpGaD
Mefloquine—Leukopenia—Dactinomycin—muscle cancer	0.000978	0.00377	CcSEcCtD
Mefloquine—Atrioventricular block—Doxorubicin—muscle cancer	0.000967	0.00373	CcSEcCtD
Mefloquine—Hepatobiliary disease—Etoposide—muscle cancer	0.000957	0.00369	CcSEcCtD
Mefloquine—Coordination abnormal—Doxorubicin—muscle cancer	0.000955	0.00368	CcSEcCtD
Mefloquine—Agranulocytosis—Etoposide—muscle cancer	0.000944	0.00364	CcSEcCtD
Mefloquine—Hepatocellular injury—Doxorubicin—muscle cancer	0.000938	0.00362	CcSEcCtD
Mefloquine—BCHE—Metabolism of proteins—TIMM10—muscle cancer	0.000936	0.00532	CbGpPWpGaD
Mefloquine—Myalgia—Dactinomycin—muscle cancer	0.00093	0.00359	CcSEcCtD
Mefloquine—Abnormal dreams—Doxorubicin—muscle cancer	0.000927	0.00358	CcSEcCtD
Mefloquine—Discomfort—Dactinomycin—muscle cancer	0.000919	0.00354	CcSEcCtD
Mefloquine—Influenza like illness—Doxorubicin—muscle cancer	0.000911	0.00351	CcSEcCtD
Mefloquine—Agitation—Vincristine—muscle cancer	0.000897	0.00346	CcSEcCtD
Mefloquine—HBA2—Metabolism—ENO2—muscle cancer	0.000894	0.00508	CbGpPWpGaD
Mefloquine—Oedema—Dactinomycin—muscle cancer	0.000892	0.00344	CcSEcCtD
Mefloquine—Aplastic anaemia—Doxorubicin—muscle cancer	0.000881	0.0034	CcSEcCtD
Mefloquine—Neuropathy—Doxorubicin—muscle cancer	0.000881	0.0034	CcSEcCtD
Mefloquine—Vertigo—Vincristine—muscle cancer	0.000877	0.00338	CcSEcCtD
Mefloquine—Hepatic failure—Methotrexate—muscle cancer	0.000875	0.00338	CcSEcCtD
Mefloquine—Leukopenia—Vincristine—muscle cancer	0.000874	0.00337	CcSEcCtD
Mefloquine—Thrombocytopenia—Dactinomycin—muscle cancer	0.000873	0.00337	CcSEcCtD
Mefloquine—ABCB1—renal system—muscle cancer	0.000862	0.00298	CbGeAlD
Mefloquine—Erythema multiforme—Etoposide—muscle cancer	0.000859	0.00331	CcSEcCtD
Mefloquine—Coma—Doxorubicin—muscle cancer	0.000857	0.00331	CcSEcCtD
Mefloquine—Eye disorder—Etoposide—muscle cancer	0.000849	0.00327	CcSEcCtD
Mefloquine—Convulsion—Vincristine—muscle cancer	0.000846	0.00326	CcSEcCtD
Mefloquine—Cardiac disorder—Etoposide—muscle cancer	0.000843	0.00325	CcSEcCtD
Mefloquine—Flushing—Etoposide—muscle cancer	0.000843	0.00325	CcSEcCtD
Mefloquine—Hypertension—Vincristine—muscle cancer	0.000843	0.00325	CcSEcCtD
Mefloquine—Myalgia—Vincristine—muscle cancer	0.000831	0.0032	CcSEcCtD
Mefloquine—Visual disturbance—Methotrexate—muscle cancer	0.00083	0.0032	CcSEcCtD
Mefloquine—Angiopathy—Etoposide—muscle cancer	0.000824	0.00318	CcSEcCtD
Mefloquine—Mediastinal disorder—Etoposide—muscle cancer	0.000819	0.00316	CcSEcCtD
Mefloquine—CYP2D6—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000817	0.00464	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000816	0.00464	CbGpPWpGaD
Mefloquine—Chills—Etoposide—muscle cancer	0.000815	0.00314	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000812	0.00313	CcSEcCtD
Mefloquine—ADORA1—G alpha (i) signalling events—CNR1—muscle cancer	0.000805	0.00457	CbGpPWpGaD
Mefloquine—Alopecia—Etoposide—muscle cancer	0.000803	0.0031	CcSEcCtD
Mefloquine—CYP2D6—head—muscle cancer	0.000802	0.00277	CbGeAlD
Mefloquine—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000801	0.00455	CbGpPWpGaD
Mefloquine—Oedema—Vincristine—muscle cancer	0.000797	0.00307	CcSEcCtD
Mefloquine—Anaphylactic shock—Vincristine—muscle cancer	0.000797	0.00307	CcSEcCtD
Mefloquine—Nervous system disorder—Vincristine—muscle cancer	0.000781	0.00301	CcSEcCtD
Mefloquine—Thrombocytopenia—Vincristine—muscle cancer	0.00078	0.00301	CcSEcCtD
Mefloquine—Decreased appetite—Dactinomycin—muscle cancer	0.000775	0.00299	CcSEcCtD
Mefloquine—CYP2D6—testis—muscle cancer	0.000775	0.00267	CbGeAlD
Mefloquine—Hyperhidrosis—Vincristine—muscle cancer	0.00077	0.00297	CcSEcCtD
Mefloquine—Fatigue—Dactinomycin—muscle cancer	0.000769	0.00296	CcSEcCtD
Mefloquine—Muscle spasms—Etoposide—muscle cancer	0.00076	0.00293	CcSEcCtD
Mefloquine—CYP19A1—Tryptophan metabolism—MDM2—muscle cancer	0.000759	0.00431	CbGpPWpGaD
Mefloquine—Hepatic failure—Doxorubicin—muscle cancer	0.000758	0.00292	CcSEcCtD
Mefloquine—Irritability—Methotrexate—muscle cancer	0.000751	0.00289	CcSEcCtD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000747	0.00424	CbGpPWpGaD
Mefloquine—Mood swings—Methotrexate—muscle cancer	0.000745	0.00287	CcSEcCtD
Mefloquine—Hypotension—Vincristine—muscle cancer	0.000744	0.00287	CcSEcCtD
Mefloquine—HBA1—Metabolism—MED12—muscle cancer	0.000743	0.00422	CbGpPWpGaD
Mefloquine—Ataxia—Methotrexate—muscle cancer	0.00074	0.00285	CcSEcCtD
Mefloquine—Feeling abnormal—Dactinomycin—muscle cancer	0.000735	0.00283	CcSEcCtD
Mefloquine—Ill-defined disorder—Etoposide—muscle cancer	0.000734	0.00283	CcSEcCtD
Mefloquine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000729	0.00281	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000726	0.0028	CcSEcCtD
Mefloquine—Insomnia—Vincristine—muscle cancer	0.000721	0.00278	CcSEcCtD
Mefloquine—Paraesthesia—Vincristine—muscle cancer	0.000715	0.00276	CcSEcCtD
Mefloquine—Malaise—Etoposide—muscle cancer	0.000713	0.00275	CcSEcCtD
Mefloquine—Dermatitis bullous—Doxorubicin—muscle cancer	0.000713	0.00275	CcSEcCtD
Mefloquine—Vertigo—Etoposide—muscle cancer	0.00071	0.00274	CcSEcCtD
Mefloquine—Leukopenia—Etoposide—muscle cancer	0.000708	0.00273	CcSEcCtD
Mefloquine—Body temperature increased—Dactinomycin—muscle cancer	0.000705	0.00272	CcSEcCtD
Mefloquine—Abdominal pain—Dactinomycin—muscle cancer	0.000705	0.00272	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.000703	0.004	CbGpPWpGaD
Mefloquine—Loss of consciousness—Etoposide—muscle cancer	0.000695	0.00268	CcSEcCtD
Mefloquine—Decreased appetite—Vincristine—muscle cancer	0.000693	0.00267	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Vincristine—muscle cancer	0.000688	0.00265	CcSEcCtD
Mefloquine—Fatigue—Vincristine—muscle cancer	0.000687	0.00265	CcSEcCtD
Mefloquine—Convulsion—Etoposide—muscle cancer	0.000685	0.00264	CcSEcCtD
Mefloquine—Hypertension—Etoposide—muscle cancer	0.000683	0.00263	CcSEcCtD
Mefloquine—HBA1—Metabolism—ENO2—muscle cancer	0.000677	0.00385	CbGpPWpGaD
Mefloquine—Chest pain—Etoposide—muscle cancer	0.000673	0.0026	CcSEcCtD
Mefloquine—Affect lability—Doxorubicin—muscle cancer	0.00067	0.00259	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000669	0.00258	CcSEcCtD
Mefloquine—Discomfort—Etoposide—muscle cancer	0.000665	0.00257	CcSEcCtD
Mefloquine—Hypersensitivity—Dactinomycin—muscle cancer	0.000657	0.00253	CcSEcCtD
Mefloquine—ABCB1—bone marrow—muscle cancer	0.000652	0.00225	CbGeAlD
Mefloquine—Gastrointestinal pain—Vincristine—muscle cancer	0.000652	0.00251	CcSEcCtD
Mefloquine—Confusional state—Etoposide—muscle cancer	0.000651	0.00251	CcSEcCtD
Mefloquine—Anaphylactic shock—Etoposide—muscle cancer	0.000645	0.00249	CcSEcCtD
Mefloquine—Mood swings—Doxorubicin—muscle cancer	0.000645	0.00249	CcSEcCtD
Mefloquine—Ataxia—Doxorubicin—muscle cancer	0.00064	0.00247	CcSEcCtD
Mefloquine—Asthenia—Dactinomycin—muscle cancer	0.00064	0.00247	CcSEcCtD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.00064	0.00363	CbGpPWpGaD
Mefloquine—Thrombocytopenia—Etoposide—muscle cancer	0.000632	0.00244	CcSEcCtD
Mefloquine—Tachycardia—Etoposide—muscle cancer	0.00063	0.00243	CcSEcCtD
Mefloquine—Body temperature increased—Vincristine—muscle cancer	0.00063	0.00243	CcSEcCtD
Mefloquine—Abdominal pain—Vincristine—muscle cancer	0.00063	0.00243	CcSEcCtD
Mefloquine—Skin disorder—Etoposide—muscle cancer	0.000627	0.00242	CcSEcCtD
Mefloquine—ABCB1—vagina—muscle cancer	0.000625	0.00216	CbGeAlD
Mefloquine—Hyperhidrosis—Etoposide—muscle cancer	0.000624	0.00241	CcSEcCtD
Mefloquine—Diarrhoea—Dactinomycin—muscle cancer	0.00061	0.00235	CcSEcCtD
Mefloquine—Pneumonia—Methotrexate—muscle cancer	0.00061	0.00235	CcSEcCtD
Mefloquine—Hypotension—Etoposide—muscle cancer	0.000603	0.00233	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000601	0.00232	CcSEcCtD
Mefloquine—Muscular weakness—Doxorubicin—muscle cancer	0.000601	0.00232	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000597	0.00339	CbGpPWpGaD
Mefloquine—Renal failure—Methotrexate—muscle cancer	0.000596	0.0023	CcSEcCtD
Mefloquine—Hypersensitivity—Vincristine—muscle cancer	0.000587	0.00226	CcSEcCtD
Mefloquine—Sweating—Methotrexate—muscle cancer	0.000581	0.00224	CcSEcCtD
Mefloquine—Paraesthesia—Etoposide—muscle cancer	0.00058	0.00223	CcSEcCtD
Mefloquine—ADORA1—GPCR ligand binding—PTCH1—muscle cancer	0.000577	0.00328	CbGpPWpGaD
Mefloquine—ABCB1—head—muscle cancer	0.000577	0.00199	CbGeAlD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000576	0.00328	CbGpPWpGaD
Mefloquine—Dyspnoea—Etoposide—muscle cancer	0.000575	0.00222	CcSEcCtD
Mefloquine—Somnolence—Etoposide—muscle cancer	0.000574	0.00221	CcSEcCtD
Mefloquine—Hepatobiliary disease—Methotrexate—muscle cancer	0.000573	0.00221	CcSEcCtD
Mefloquine—Asthenia—Vincristine—muscle cancer	0.000572	0.0022	CcSEcCtD
Mefloquine—Vomiting—Dactinomycin—muscle cancer	0.000567	0.00219	CcSEcCtD
Mefloquine—Agranulocytosis—Methotrexate—muscle cancer	0.000566	0.00218	CcSEcCtD
Mefloquine—Rash—Dactinomycin—muscle cancer	0.000562	0.00217	CcSEcCtD
Mefloquine—Decreased appetite—Etoposide—muscle cancer	0.000561	0.00216	CcSEcCtD
Mefloquine—ABCB1—testis—muscle cancer	0.000557	0.00192	CbGeAlD
Mefloquine—Gastrointestinal disorder—Etoposide—muscle cancer	0.000557	0.00215	CcSEcCtD
Mefloquine—Fatigue—Etoposide—muscle cancer	0.000556	0.00215	CcSEcCtD
Mefloquine—Diarrhoea—Vincristine—muscle cancer	0.000545	0.0021	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—FOXO4—muscle cancer	0.000541	0.00307	CbGpPWpGaD
Mefloquine—Feeling abnormal—Etoposide—muscle cancer	0.000532	0.00205	CcSEcCtD
Mefloquine—Nausea—Dactinomycin—muscle cancer	0.00053	0.00204	CcSEcCtD
Mefloquine—Pneumonia—Doxorubicin—muscle cancer	0.000528	0.00204	CcSEcCtD
Mefloquine—Gastrointestinal pain—Etoposide—muscle cancer	0.000528	0.00204	CcSEcCtD
Mefloquine—Dizziness—Vincristine—muscle cancer	0.000527	0.00203	CcSEcCtD
Mefloquine—Visual impairment—Methotrexate—muscle cancer	0.000524	0.00202	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00052	0.00201	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000519	0.00295	CbGpPWpGaD
Mefloquine—Renal failure—Doxorubicin—muscle cancer	0.000516	0.00199	CcSEcCtD
Mefloquine—Erythema multiforme—Methotrexate—muscle cancer	0.000514	0.00198	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000514	0.00198	CcSEcCtD
Mefloquine—Urticaria—Etoposide—muscle cancer	0.000513	0.00198	CcSEcCtD
Mefloquine—Body temperature increased—Etoposide—muscle cancer	0.00051	0.00197	CcSEcCtD
Mefloquine—Abdominal pain—Etoposide—muscle cancer	0.00051	0.00197	CcSEcCtD
Mefloquine—Eye disorder—Methotrexate—muscle cancer	0.000509	0.00196	CcSEcCtD
Mefloquine—Tinnitus—Methotrexate—muscle cancer	0.000507	0.00196	CcSEcCtD
Mefloquine—Vomiting—Vincristine—muscle cancer	0.000507	0.00195	CcSEcCtD
Mefloquine—Cardiac disorder—Methotrexate—muscle cancer	0.000505	0.00195	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—muscle cancer	0.000503	0.00194	CcSEcCtD
Mefloquine—Rash—Vincristine—muscle cancer	0.000502	0.00194	CcSEcCtD
Mefloquine—Dermatitis—Vincristine—muscle cancer	0.000502	0.00194	CcSEcCtD
Mefloquine—Headache—Vincristine—muscle cancer	0.000499	0.00192	CcSEcCtD
Mefloquine—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000496	0.00191	CcSEcCtD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000494	0.00281	CbGpPWpGaD
Mefloquine—Angiopathy—Methotrexate—muscle cancer	0.000494	0.0019	CcSEcCtD
Mefloquine—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000493	0.0028	CbGpPWpGaD
Mefloquine—Mediastinal disorder—Methotrexate—muscle cancer	0.00049	0.00189	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—muscle cancer	0.00049	0.00189	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000489	0.00278	CbGpPWpGaD
Mefloquine—Chills—Methotrexate—muscle cancer	0.000488	0.00188	CcSEcCtD
Mefloquine—ADORA1—GPCR ligand binding—CNR1—muscle cancer	0.000487	0.00277	CbGpPWpGaD
Mefloquine—Alopecia—Methotrexate—muscle cancer	0.000481	0.00185	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—muscle cancer	0.00048	0.00185	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—muscle cancer	0.000477	0.00184	CcSEcCtD
Mefloquine—Hypersensitivity—Etoposide—muscle cancer	0.000476	0.00183	CcSEcCtD
Mefloquine—Erythema—Methotrexate—muscle cancer	0.000474	0.00183	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—muscle cancer	0.000474	0.00183	CcSEcCtD
Mefloquine—Nausea—Vincristine—muscle cancer	0.000473	0.00182	CcSEcCtD
Mefloquine—Asthenia—Etoposide—muscle cancer	0.000463	0.00179	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—muscle cancer	0.000463	0.00179	CcSEcCtD
Mefloquine—Pruritus—Etoposide—muscle cancer	0.000457	0.00176	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—muscle cancer	0.000454	0.00175	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—muscle cancer	0.000446	0.00172	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—PTCH1—muscle cancer	0.000446	0.00253	CbGpPWpGaD
Mefloquine—Erythema multiforme—Doxorubicin—muscle cancer	0.000445	0.00172	CcSEcCtD
Mefloquine—ADORA1—Signaling Pathways—KIDINS220—muscle cancer	0.000444	0.00253	CbGpPWpGaD
Mefloquine—Diarrhoea—Etoposide—muscle cancer	0.000442	0.0017	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—muscle cancer	0.00044	0.0017	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—muscle cancer	0.00044	0.00169	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—muscle cancer	0.000439	0.00169	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—muscle cancer	0.000437	0.00169	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—muscle cancer	0.000437	0.00169	CcSEcCtD
Mefloquine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000434	0.00247	CbGpPWpGaD
Mefloquine—Angiopathy—Doxorubicin—muscle cancer	0.000427	0.00165	CcSEcCtD
Mefloquine—Malaise—Methotrexate—muscle cancer	0.000427	0.00165	CcSEcCtD
Mefloquine—Dizziness—Etoposide—muscle cancer	0.000427	0.00165	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—muscle cancer	0.000426	0.00164	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—muscle cancer	0.000425	0.00164	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—muscle cancer	0.000424	0.00163	CcSEcCtD
Mefloquine—Chills—Doxorubicin—muscle cancer	0.000423	0.00163	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—muscle cancer	0.000416	0.00161	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—muscle cancer	0.000413	0.00159	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—muscle cancer	0.00041	0.00158	CcSEcCtD
Mefloquine—Vomiting—Etoposide—muscle cancer	0.00041	0.00158	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—muscle cancer	0.00041	0.00158	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—muscle cancer	0.00041	0.00158	CcSEcCtD
Mefloquine—Rash—Etoposide—muscle cancer	0.000407	0.00157	CcSEcCtD
Mefloquine—Dermatitis—Etoposide—muscle cancer	0.000407	0.00157	CcSEcCtD
Mefloquine—Headache—Etoposide—muscle cancer	0.000404	0.00156	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—muscle cancer	0.000403	0.00156	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—muscle cancer	0.000403	0.00156	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—muscle cancer	0.000403	0.00156	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.0004	0.00154	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—FOXO1—muscle cancer	0.000399	0.00227	CbGpPWpGaD
Mefloquine—Discomfort—Methotrexate—muscle cancer	0.000398	0.00154	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000396	0.00225	CbGpPWpGaD
Mefloquine—Muscle spasms—Doxorubicin—muscle cancer	0.000394	0.00152	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—muscle cancer	0.00039	0.0015	CcSEcCtD
Mefloquine—Anaphylactic shock—Methotrexate—muscle cancer	0.000387	0.00149	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—muscle cancer	0.000387	0.00149	CcSEcCtD
Mefloquine—Nausea—Etoposide—muscle cancer	0.000383	0.00148	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—muscle cancer	0.000381	0.00147	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—muscle cancer	0.000379	0.00146	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—muscle cancer	0.000379	0.00146	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—muscle cancer	0.000377	0.00145	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—CNR1—muscle cancer	0.000376	0.00214	CbGpPWpGaD
Mefloquine—Skin disorder—Methotrexate—muscle cancer	0.000376	0.00145	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—muscle cancer	0.000374	0.00144	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—muscle cancer	0.00037	0.00143	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—muscle cancer	0.000369	0.00142	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—muscle cancer	0.000368	0.00142	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—muscle cancer	0.000367	0.00142	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—muscle cancer	0.000362	0.0014	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—muscle cancer	0.000361	0.00139	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—muscle cancer	0.000361	0.00139	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—muscle cancer	0.000355	0.00137	CcSEcCtD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000355	0.00202	CbGpPWpGaD
Mefloquine—Hypertension—Doxorubicin—muscle cancer	0.000354	0.00137	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000352	0.00136	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—muscle cancer	0.00035	0.00135	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—muscle cancer	0.000349	0.00135	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—muscle cancer	0.000349	0.00135	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—muscle cancer	0.000349	0.00135	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—muscle cancer	0.000348	0.00134	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—muscle cancer	0.000347	0.00134	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000347	0.00134	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—muscle cancer	0.000345	0.00133	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—muscle cancer	0.000345	0.00133	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—muscle cancer	0.000344	0.00133	CcSEcCtD
Mefloquine—ADORA2A—Signaling Pathways—KIDINS220—muscle cancer	0.000343	0.00195	CbGpPWpGaD
Mefloquine—Dyspepsia—Methotrexate—muscle cancer	0.00034	0.00131	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—muscle cancer	0.000338	0.0013	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—muscle cancer	0.000336	0.0013	CcSEcCtD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000335	0.0019	CbGpPWpGaD
Mefloquine—Anaphylactic shock—Doxorubicin—muscle cancer	0.000335	0.00129	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—muscle cancer	0.000335	0.00129	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000334	0.00129	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—muscle cancer	0.000333	0.00129	CcSEcCtD
Mefloquine—Shock—Doxorubicin—muscle cancer	0.000329	0.00127	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—muscle cancer	0.000328	0.00127	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—muscle cancer	0.000328	0.00126	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—muscle cancer	0.000327	0.00126	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—muscle cancer	0.000325	0.00125	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—muscle cancer	0.000324	0.00125	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—muscle cancer	0.000319	0.00123	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—muscle cancer	0.000316	0.00122	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—muscle cancer	0.000313	0.00121	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000312	0.00177	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—PTGS2—muscle cancer	0.000311	0.00177	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000308	0.00175	CbGpPWpGaD
Mefloquine—Urticaria—Methotrexate—muscle cancer	0.000307	0.00118	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—muscle cancer	0.000306	0.00118	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—muscle cancer	0.000306	0.00118	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000305	0.00118	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—KIT—muscle cancer	0.000304	0.00173	CbGpPWpGaD
Mefloquine—Insomnia—Doxorubicin—muscle cancer	0.000303	0.00117	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—muscle cancer	0.000301	0.00116	CcSEcCtD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000299	0.0017	CbGpPWpGaD
Mefloquine—Dyspnoea—Doxorubicin—muscle cancer	0.000298	0.00115	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—muscle cancer	0.000298	0.00115	CcSEcCtD
Mefloquine—ADORA1—Signaling by GPCR—PTCH1—muscle cancer	0.000296	0.00168	CbGpPWpGaD
Mefloquine—Dyspepsia—Doxorubicin—muscle cancer	0.000295	0.00114	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000293	0.00167	CbGpPWpGaD
Mefloquine—Decreased appetite—Doxorubicin—muscle cancer	0.000291	0.00112	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000289	0.00111	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—muscle cancer	0.000289	0.00111	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—muscle cancer	0.000285	0.0011	CcSEcCtD
Mefloquine—Asthenia—Methotrexate—muscle cancer	0.000277	0.00107	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—muscle cancer	0.000276	0.00106	CcSEcCtD
Mefloquine—ADORA1—GPCR downstream signaling—CNR1—muscle cancer	0.000275	0.00156	CbGpPWpGaD
Mefloquine—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000274	0.00106	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—muscle cancer	0.000274	0.00105	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—muscle cancer	0.000266	0.00103	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—muscle cancer	0.000265	0.00102	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—muscle cancer	0.000265	0.00102	CcSEcCtD
Mefloquine—Diarrhoea—Methotrexate—muscle cancer	0.000265	0.00102	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000264	0.0015	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—FH—muscle cancer	0.000264	0.0015	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.00026	0.00148	CbGpPWpGaD
Mefloquine—Dizziness—Methotrexate—muscle cancer	0.000256	0.000986	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000255	0.00145	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000255	0.00145	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CNR1—muscle cancer	0.00025	0.00142	CbGpPWpGaD
Mefloquine—Hypersensitivity—Doxorubicin—muscle cancer	0.000247	0.000951	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—muscle cancer	0.000246	0.000948	CcSEcCtD
Mefloquine—Rash—Methotrexate—muscle cancer	0.000244	0.00094	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—muscle cancer	0.000244	0.000939	CcSEcCtD
Mefloquine—CYP19A1—Metabolism—FH—muscle cancer	0.000243	0.00138	CbGpPWpGaD
Mefloquine—Headache—Methotrexate—muscle cancer	0.000242	0.000934	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—muscle cancer	0.00024	0.000926	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—MDM2—muscle cancer	0.00024	0.00136	CbGpPWpGaD
Mefloquine—Pruritus—Doxorubicin—muscle cancer	0.000237	0.000913	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—TP53—muscle cancer	0.000236	0.00134	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PTGS2—muscle cancer	0.000236	0.00134	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—FH—muscle cancer	0.000236	0.00134	CbGpPWpGaD
Mefloquine—Nausea—Methotrexate—muscle cancer	0.00023	0.000885	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—muscle cancer	0.000229	0.000883	CcSEcCtD
Mefloquine—ADORA2A—Signaling by GPCR—PTCH1—muscle cancer	0.000229	0.0013	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000227	0.00129	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000223	0.00127	CbGpPWpGaD
Mefloquine—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000221	0.00126	CbGpPWpGaD
Mefloquine—Dizziness—Doxorubicin—muscle cancer	0.000221	0.000854	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—muscle cancer	0.000213	0.000821	CcSEcCtD
Mefloquine—ADORA2A—GPCR downstream signaling—CNR1—muscle cancer	0.000213	0.00121	CbGpPWpGaD
Mefloquine—Rash—Doxorubicin—muscle cancer	0.000211	0.000814	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—muscle cancer	0.000211	0.000813	CcSEcCtD
Mefloquine—Headache—Doxorubicin—muscle cancer	0.00021	0.000809	CcSEcCtD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000205	0.00116	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000201	0.00114	CbGpPWpGaD
Mefloquine—Nausea—Doxorubicin—muscle cancer	0.000199	0.000767	CcSEcCtD
Mefloquine—ACHE—Neuronal System—MDM2—muscle cancer	0.000195	0.00111	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CNR1—muscle cancer	0.000193	0.0011	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—TP53—muscle cancer	0.000182	0.00104	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—VEGFA—muscle cancer	0.000177	0.00101	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTCH1—muscle cancer	0.000175	0.000994	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—MDM2—muscle cancer	0.000174	0.00099	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—IGF2—muscle cancer	0.000173	0.000982	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.000168	0.000956	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—IGF2—muscle cancer	0.000154	0.000876	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000152	0.000862	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—FOXO4—muscle cancer	0.00015	0.000855	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—MED12—muscle cancer	0.000149	0.000848	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CNR1—muscle cancer	0.000148	0.000839	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—MED12—muscle cancer	0.000137	0.00078	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ENO2—muscle cancer	0.000136	0.000773	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTCH1—muscle cancer	0.000135	0.000768	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—MED12—muscle cancer	0.000133	0.000757	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ENO2—muscle cancer	0.000125	0.000711	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ENO2—muscle cancer	0.000121	0.00069	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IGF2—muscle cancer	0.000121	0.000686	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FOXO4—muscle cancer	0.000116	0.00066	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000115	0.000654	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—FH—muscle cancer	0.000115	0.000653	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CNR1—muscle cancer	0.000114	0.000648	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—FOXO1—muscle cancer	0.000111	0.000631	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000111	0.00063	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—FH—muscle cancer	0.000108	0.000616	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000106	0.000605	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	9.78e-05	0.000556	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	9.5e-05	0.00054	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IGF2—muscle cancer	9.32e-05	0.00053	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	8.74e-05	0.000497	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FOXO1—muscle cancer	8.58e-05	0.000487	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KIT—muscle cancer	8.47e-05	0.000481	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—FH—muscle cancer	7.09e-05	0.000403	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MDM2—muscle cancer	6.67e-05	0.000379	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	6.6e-05	0.000375	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KIT—muscle cancer	6.54e-05	0.000371	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—MED12—muscle cancer	6.5e-05	0.000369	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MED12—muscle cancer	6.12e-05	0.000348	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ENO2—muscle cancer	5.92e-05	0.000337	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ENO2—muscle cancer	5.58e-05	0.000317	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MDM2—muscle cancer	5.15e-05	0.000293	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—muscle cancer	5.06e-05	0.000288	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—muscle cancer	4.74e-05	0.000269	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—muscle cancer	4.36e-05	0.000248	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—muscle cancer	4.23e-05	0.00024	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MED12—muscle cancer	4e-05	0.000227	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—muscle cancer	3.91e-05	0.000222	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—muscle cancer	3.83e-05	0.000217	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ENO2—muscle cancer	3.65e-05	0.000207	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—muscle cancer	2.95e-05	0.000168	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—muscle cancer	2.06e-05	0.000117	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—muscle cancer	1.94e-05	0.00011	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—muscle cancer	1.27e-05	7.22e-05	CbGpPWpGaD
